NCT05179954Recruiting
Lipoprotein Kinetics in T1D
Apolipoprotein C3-loading of Apolipoprotein B100 Lipoproteins and Cardiovascular Disease in Patients With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 22 Nov 2021
- Start date
- 9 May 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Missouri-Columbia
- Diseases
- Type 1 diabetes
- NCT number
- NCT05179954
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 9 May 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism
Other illness
- hypothyroidism or other disorders known to affect lipid metabolism
- conditions that would make it impossible to complete the study protocol
Other
- more than 1.5 h of structured exercise/week
Who the study is looking for
- Age: ≥18 but ≤45 years
- premenopausal/eumenorrheic and not pregnant or breastfeeding
- non-obese (body mass index ≥18.5\<30.0 kg/m2)
- Fasting plasma triglyceride \<150 mg/dL
- Additional inclusion criteria for control subjects:
- Fasting plasma glucose \<100 mg/dL
- Plasma glucose 2 h after a 75 g oral glucose challenge \<140 mg/dL
- HbA1c \<5.6%.
- Additional inclusion criteria for subjects with T1DM:
- stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening
- no use of diabetes medications other than insulin
- HbA1c \<8.0%, basal (overnight fasted)
- no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing
Age in the registry: 18 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Missouri School of Medicine Coordinator of this site? Confirm its status | Columbia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.